| Theme | Up‒to‒date of the Protection of Gastroenterological Cancers | |
|---|---|---|
| Title | Inflammatory Bowel Disease and Colitic Cancer | |
| Publish Date | 2015/10 | |
| Author | Minoru Fukuchi | Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University |
| Author | Noriyasu Chika | Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University |
| Author | Toru Ishiguro | Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University |
| Author | Keiichiro Ishibashi | Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University |
| Author | Erito Mochiki | Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University |
| Author | Hideyuki Ishida | Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University |
| [ Summary ] | Patients with inflammatory bowel disease (IBD), ulcerative colitis (UC), and Crohn's disease (CD), have an increased risk of developing colorectal or small bowel cancer compared with the general population. Surveillance colonoscopy has been proposed according to the risk of colorectal cancer (CRC) worldwide. IBD‒associated CRC is known as colitic cancer. In particular, UC patients with high‒grade dysplasia or dysplasia‒associated lesion or mass (DALM) should be treated with proctocolectomy and ileal pouch anal anastomosis to decrease the risk of colitic cancer. The available drug options for IBD have potential utility as cancer chemoprevention agents for UC patients. The benefit of surgical resection for patients with low‒grade dysplasia remains controversial. | |